A prospective, randomized controlled trial assessing the efficacy and safety of cilostazol and aspirin therapy versus aspirin therapy for the prevention of vascular events in patietns undergoing coronary stent implantatio
Not Applicable
- Conditions
- Coronary artery disease patients undergoing coronary stent implantation
- Registration Number
- JPRN-UMIN000012541
- Lead Sponsor
- Koseikai Takai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
1) hemostatic disorder or active pathologic bleeding, including hemophilia, capillary fragility, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemoptysis and vitreous hemorrhage 2) Known allergy to aspirin or cilostazol 3) Malignancies or other comorbid conditions with a life expectancy of less than 2 years 4) Planned major surgery necessitating discontinuation of antiplatelet therapy within the 2 years after enrollment 5) Pregnancy 6) Circumstances that would have made follow-up impossible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method